Ajanta Pharma FY24 Annual Earnings Summary
4 quarters covered · ₹4,208 Cr revenue · ₹816 Cr PAT · 27.0% average EBITDA margin.
Quarter-by-quarter progression
Management promises made during the year
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q2 FY24Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
Q3 FY24Risks flagged during the year
While current price erosion is stable at high single digits, any acceleration could impact US generics profitability and overall margins.
Q1 FY24 · mediumAfrica institutional (anti-malarial) sales declined 16% YoY due to unpredictable procurement agency funding.
Q1 FY24 · mediumChantix launch depends on FDA approval; management could not provide a firm timeline, citing regulatory dependence.
Q1 FY24 · mediumWhile price erosion has moderated to high single digits, further acceleration remains a risk given market dynamics.
Q2 FY24 · mediumAsia branded sales declined 8% YoY in Q2 due to supplies pushed to next quarter; recovery depends on execution.
Q2 FY24 · mediumAfrica branded business saw a slowdown in the market over the last 4-5 months; growth recovery is uncertain.
Q2 FY24 · mediumChantix launch is delayed to Q4 FY24 or Q1 FY25; any further delay could impact US revenue expectations.
Q2 FY24 · mediumManagement confirmed high single-digit price erosion in US base portfolio, which could pressure margins if volumes don't compensate.
Q3 FY24 · mediumFreight costs may increase by ~0.5% of revenue (~INR 30-35 crore) and transit times by 15-20 days, potentially pressuring margins and working capital.
Q3 FY24 · mediumInstitutional business is lumpy and dependent on agency funding and malaria season, making it difficult to forecast.
Q3 FY24 · mediumCardiology growth was lower than IPM due to price revision in a major product in December 2022, and competitive intensity has increased.
Q4 FY24 · mediumIncreased transit times and freight costs due to Red Sea crisis could add ~INR 30 crore to expenses, potentially pressuring margins.
What changed through the year
Q1 FY24 · Mid-teen revenue growth for FY24
Management expects mid-teen percentage growth for the full year across branded generics and US generics.
Q1 FY24 · EBITDA margin of 25% ±1% for FY24
EBITDA margin guided at 25% ±1% for FY24, supported by gross margin stability and cost control.
Q1 FY24 · US generics revenue similar level in next three quarters
US generics revenue expected to remain at similar levels as Q1 (₹213 crore) for the next three quarters.
Q1 FY24 · CapEx of ₹200 crore for FY24
Capital expenditure for FY24 estimated at ₹200 crore, including maintenance and new corporate house CapEx.
Q2 FY24 · FY24 EBITDA margin guidance upgraded to ~26%
Management expects EBITDA margin of around 26% for FY24, up from earlier guidance of 25%, due to improved gross margins and lower logistics costs.
Q2 FY24 · Asia branded business to deliver low-teens growth in FY24
Despite an 8% decline in Q2, management expects Asia branded business to post low-teens growth for the full year, driven by recovery in H2.
Q2 FY24 · Africa branded business to deliver low-teens growth in FY24
Africa branded business is expected to bounce back and deliver low-teens growth for FY24, after a flattish H1.
Q2 FY24 · US revenues to sustain at similar levels for next two quarters
Management expects US generics revenue to remain at Q2 levels for the next two quarters, factoring in new launches and market share changes.
Q3 FY24 · FY24 EBITDA margin guidance revised to 27% ±1%
Management revised full-year EBITDA margin guidance to 27% ±1%, down from 28% in 9M, due to higher freight costs from Red Sea crisis and increased Q4 expenses.
Q3 FY24 · India business to grow low double digits in FY24
India business expected to grow 12-13% for full year FY24, with Q4 aspiration to cross 15%.
Q3 FY24 · Asia branded to grow low teens in FY24
Asia branded business expected to grow low double digits for full year FY24.
Q3 FY24 · Africa branded to grow mid to high single digits in FY24
Africa branded business expected to grow mid to high single digits for full year FY24.
Q4 FY24 · Overall revenue growth of low teens in FY25
Management expects consolidated revenue to grow in low teens, with branded generics growing mid-teens and US generics in mid-single digits.
Q4 FY24 · India business to grow 10-11% in FY25
India branded generics are expected to grow 200-300 bps faster than IPM (forecast ~8%), implying 10-11% growth.
Q4 FY24 · EBITDA margin to sustain at ~28% in FY25
Management guided for EBITDA margin of ~28% for FY25, with potential 100 bps improvement if freight costs normalize.
Q4 FY24 · CapEx of INR 175-200 crore in FY25
Capital expenditure for FY25 is estimated at INR 175-200 crore, including maintenance capex.